Short answer
Kodiak Sciences Inc. (KOD) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release covers Q3 2026 financial results for quarter ended September 30, 2026.
Kodiak Sciences Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release covers Q3 2026 financial results for quarter ended September 30, 2026
- Business highlights accompany the quarterly results
- Exhibit 99.1 contains the detailed financial results and operating updates
Item EX-99.1 · Exhibit EX-99.1
- Zenkuda met DAYBREAK’s primary endpoint with p-value 0.0007, 54% of patients achieving 6-month dosing, supporting planned multi-indication BLA submission in Q4 2026
- Tabirafusp-ted met vision and anatomical endpoints with p-values 0.0036 and <0.0001, while Phase 3 ALTO enrollment advances in diabetic macular edema
- KSI-101 PEAK first 300-patient cohort completed, with pivotal topline data expected December 2026 and potential BLA filing targeted for Q2 2027
- Cash $88.7M at September 30, 2026, supplemented by $69M net ATM proceeds after quarter-end, extending operations into 2027
- Q3 net loss $66.2M, or $1.05 per share, with R&D expense rising to $58.3M as late-stage trial and manufacturing activity accelerates
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Kodiak Sciences Inc. 8-K filings
Get the next KOD 8-K as it lands
Follow KOD for push alerts, or ask the research agent what this filing means.